Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methylglyoxal (MG) is a highly reactive α-dicarbonyl metabolite primarily produced as a byproduct of the glycolytic pathway through the non-enzymatic degradation of triose phosphates (Source: PubMed, PMID: 24563827). It serves as the principal precursor for the formation of advanced glycation end-products (AGEs), which are irreversible modifications of proteins and DNA that accumulate during aging and diabetes (Source: NIH, StatPearls). Elevated levels of MG lead to "dicarbonyl stress," causing structural and functional damage to long-lived proteins such as collagen and basement membrane components, thereby contributing to diabetic nephropathy, retinopathy, and cardiovascular complications (Source: Nature Reviews Drug Discovery). Pharmacological targeting of MG involves the use of small-molecule scavengers like aminoguanidine and pyridoxamine, which neutralize the reactive carbonyl group before it can modify proteins (Source: PubChem). Additionally, therapeutic strategies include the activation of the glyoxalase system, particularly Glyoxalase 1 (GLO1), to accelerate the enzymatic detoxification of MG into D-lactate (Source: UniProt). Metformin, a first-line treatment for type 2 diabetes, has also been shown to possess MG-scavenging properties, contributing to its vascular protective effects (Source: PubMed, PMID: 27535878). Despite the potential of MG-targeting agents, clinical development has been hindered by safety concerns, including off-target reactivity with essential vitamins like pyridoxal phosphate and lack of long-term efficacy in human trials (Source: Wikipedia, Advanced Glycation End-product).
Direct chemical scavenging of reactive dicarbonyl species, inhibition of non-enzymatic glycation, breaking of established advanced glycation end-product (AGE) cross-links, and pharmacological induction of the glyoxalase 1 (GLO1) detoxification enzyme.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methylglyoxal (MG) (MG).